Patents by Inventor Dixiang LUO

Dixiang LUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion protein having triple activity and use thereof
    Patent number: 12729231
    Abstract: A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.
    Type: Grant
    Filed: March 3, 2026
    Date of Patent: September 8, 2026
    Assignee: SHANGHAI MINWEI BIOTECHNOLOGY CO., LTD
    Inventors: Weiyue Han, Guitao Zhang, Dixiang Luo, Wenxin Song, Shaodong Zhong, Dan Liu, Jiangtao Peng
  • FUSION PROTEIN HAVING TRIPLE ACTIVITY AND USE THEREOF
    Publication number: 20260176323
    Abstract: A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.
    Type: Application
    Filed: March 3, 2026
    Publication date: June 25, 2026
    Inventors: Weiyue HAN, Guitao ZHANG, Dixiang LUO, Wenxin SONG, Shaodong ZHONG, Dan LIU, Jiangtao PENG
  • FUSION PROTEIN HAVING TRIPLE ACTIVITY AND USE THEREOF
    Publication number: 20260125444
    Abstract: A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.
    Type: Application
    Filed: January 18, 2023
    Publication date: May 7, 2026
    Inventors: Weiyue HAN, Guitao ZHANG, Dixiang LUO, Wenxin SONG, Shaodong ZHONG, Dan LIU, Jiangtao PENG
  • INCRETIN ANALOG AND USE THEREOF
    Publication number: 20260055155
    Abstract: An incretin analog and a use thereof are provided. The incretin analog contains a triple agonist protein for activating a human glucose-dependent insulinotropic polypeptide (GIP) receptor, a glucagon-like peptide-1 (GLP-1) receptor, and a glucagon (GCG) receptor, and can be used for treating type 2 diabetes (T2D), obesity, non-alcoholic steatohepatitis, and other glycolipid metabolism disorders.
    Type: Application
    Filed: March 20, 2024
    Publication date: February 26, 2026
    Inventors: Weiyue HAN, Guitao ZHANG, Dixiang LUO, Shaodong ZHONG, Wenxin SONG
  • HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230322877
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Application
    Filed: June 13, 2023
    Publication date: October 12, 2023
    Inventors: John Li, Shengwei Li, Dixiang Luo, Yiran Wu, Ming Zhou, Yang Wang, Xiaolei Zhuang, Liang Hua, Pengyi Luo
  • Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
    Patent number: 11718652
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 8, 2023
    Assignees: Salubris Biotherapeutics, Inc.
    Inventors: John Li, Shengwei Li, Dixiang Luo, Yiran Wu, Ming Zhou, Yang Wang, Xiaolei Zhuang, Liang Hua, Pengyi Luo
  • HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210347841
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Application
    Filed: May 21, 2021
    Publication date: November 11, 2021
    Inventors: John LI, Shengwei LI, Dixiang LUO, Yiran WU, Ming ZHOU, Yang WANG, Xiaolei ZHUANG, Liang HUA, Pengyi LUO
  • Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
    Patent number: 11046741
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 29, 2021
    Assignees: Salubris Biotherapeutics, Inc., Salubris (Chengdu) Biotech Co., Ltd.
    Inventors: John Li, Shengwei Li, Dixiang Luo, Yiran Wu, Ming Zhou, Xiaolei Zhuang, Liang Hua, Pengyi Luo, Yang Wang
  • HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200010522
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Application
    Filed: April 11, 2019
    Publication date: January 9, 2020
    Inventors: John LI, Shengwei LI, Dixiang LUO, Yiran WU, Ming ZHOU, Xiaolei Zhuang, Liang HUA, Pengyi LUO, Yang WANG